Elan Corporation
http://www.elan.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Elan Corporation
The Long Learning Curve For Artificially Intelligent Drug Manufacturing Begins Now
Drugmakers quickly adopt low-impact AI/ML models in quest to eventually automate manufacturing processes. Already, they are learning a lot about how these models can support their operations. One finding: innovative change management approaches may be required to unlock their full potential.
Preterm Birth Patients Sought By US FDA As Meeting On Treatment Development Looms
With the only FDA-approved treatment off the market, the FDA is looking for ideas for development of new preterm birth treatments.
US FDA’s Sentinel System Strives To Stay Ahead Of Its Own Success
The sprawling safety surveillance system is propelling advances in informatics and advanced analytics, but the agency is delaying next contracting cycle to digest its experience.
More Than Just Humira: US Biosimilars Enjoy An Eventful 2023
The launch of competition to Humira was the main event for US biosimilars this year – but a number of other key developments also took place in 2023, including settlements on Stelara that set up a series of launches in 2025, as well as first approvals for ustekinumab, natalizumab and tocilizumab biosimilars.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Onclave Therapeutics Limited
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice